Hemoadsorption therapy outcomes study
Part of Heart & circulation clinical trials.
This trial looks at how a blood-filtering treatment called hemoadsorption affects patients' health and lab results. It may help people who are already receiving this therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have received CytoSorb or Efferon LPS hemoadsorption treatment.
- Your doctors must have recorded your lab results and clinical data before and after treatment.
- Your key details like age, treatment type, and timing must be available for the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a blood-filtering treatment for people in septic shock, a severe reaction to infection. It aims to see if removing harmful substances from the blood can help recovery.
This trial tests a special blood filter called Oxiris that may help remove toxins and inflammation from the blood in patients with septic shock. It aims to see if this treatment can improve outcomes for people who need kidney replacement therapy.
This trial tests whether filtering inflammatory substances from the blood using a special device can improve recovery in people with severe ischemic stroke. You must be within 48 hours of stroke onset and have significant disability or large areas of brain injury.
This trial tests a blood-filtering device (CytoSorb) that may help control the overwhelming immune response and improve blood vessel function in people with severe septic shock. It's for patients who need strong medications to keep their blood pressure up and who haven't improved with standard care.
This study tests whether a blood-filter treatment used during a heart transplant can improve how the transplant goes for adults. You might be eligible if you’re having a heart transplant and meet the specific medication and procedure requirements.
This study tests a long-term, high-flow hemoadsorption therapy for people on maintenance hemodialysis. It aims to see if the treatment can improve outcomes for those with uremia (built-up waste in the blood).
Hear when a new Hemoadsorption trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.